The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by small patient populations worldwide to treat a variety of rare diseases and serious medical conditions. PPTA works globally to: • Advocate for access to and affordability of therapies for patients • Engage in constructive dialogue with regulatory agencies • Collaborate with patient advocacy organizations PPTA also administers standards and programs that help ensure the quality and safety of plasma collection and manufacturing and protect both donors and patients.